Venous thromboembolism
Jun 1, 2025, 03:33
Blood Advances Study Reveals Misclassification of Venous Thromboembolism (VTE) Risk
American Society of Hematology shared a post on X:
“Venous thromboembolism (VTE) affects 1 million Americans yearly. A recent study in Blood Advances shows 1 in 3 medical patients had misclassified VTE risk, leading to inappropriate treatment for half. ”
Accurate VTE risk assessment is essential to avoid both under- and overtreatment. This study draws attention to how often patients are misclassified.
Check out the full study here.
Get the latest news on Hemostasis Today.
-
Oct 18, 2026, 02:43Priya Sriskandarajah: Diagnosis and Management of PV and JAK2-Unmutated Erythrocytosis
-
Oct 18, 2026, 02:41C. Michael Gibson: A Meta-Analysis of DOACs and DAPT After Left Atrial Appendage Closure
-
Oct 18, 2026, 02:27What Hematologists Should Remember About the Person Behind the Platelet Count – ASH
-
Oct 18, 2026, 01:44Marta Velia Antonini: How to Deliver CRRT during ECMO?
-
Oct 18, 2026, 01:19Aamir Saeed: Anticoagulation, Cirrhosis, and Other Risk Factors for Post-ERCP Bleeding
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day